Hypochondriasis

10/01/2022 - "CBT and SSRIs are effective in the acute treatment of hypochondriasis, with some indication that intervention at a younger age produces better outcomes for CBT. "
06/01/2011 - ": A substantial proportion of patients with hypochondriasis who receive treatment with SSRIs achieve remission over the long term. "
01/01/1996 - "We review the case reports and small uncontrolled series on the pharmacologic treatment of hypochondriasis, emphasizing the growing body of evidence suggesting particular efficacy for the serotonin reuptake inhibitors. "
10/01/2022 - "Meta-analysis of cognitive behaviour therapy and selective serotonin reuptake inhibitors for the treatment of hypochondriasis: Implications for trial design."
07/01/2011 - "When both study samples were pooled, we found associations for anxiety (psychic; selective serotonin reuptake inhibitors arm), somatic (gastrointestinal), and hypochondriasis (Hypericum arm), and anxiety (psychic) and somatic (general) symptoms (placebo arm). "

05/01/2017 - "UMIs might be a transdiagnostic variable across different disorders such as OCD, BDD, EDs, and Hypochondriasis, and they might contribute to explaining the phenomenological similarities among them."
08/01/2014 - "We aimed to generate reference values for a healthy population and for a population of patients fulfilling diagnostic criteria for at least one of BDD, hypochondriasis, and CFS, treated in specialized mental health care. "
01/01/2006 - "Current practice in DSM-IV is to classify OCD, BDD or hypochondriasis and a delusional disorder as separate entities; this way of classifying seems to be an artefact. "
01/01/2006 - "For instance, OCD, hypochondriasis, BDD and to a lesser degree anorexia nervosa can all be particularized as 'with good insight', 'with poor insight' or 'with psychotic features'. "
06/01/1995 - "Future research may indicate that obsessional disorders such as BDD, anorexia, OCD, and hypochondriasis, as well as other disorders such as major depression, should have qualifiers or subtypes--for example, "with good insight," "with poor insight," and "with delusional (or psychotic) thinking"--with an implied continuum of insight embraced by a single disorder. "

02/01/1999 - "SSRI antidepressants are effective for treating delusional hypochondriasis."
10/01/1976 - "The results indicate that these patients showed a consistent syndrome with the following features: a) anergic endogenous depression; b) positive family history in first degree probands; c) obsessional personality traits and symptoms; d) hypochondriasis and somatic symptoms; e) failure to respond to previous antidepressant therapy with tricyclic and MAOI compounds as well as ECT. "
01/01/2018 - "The majority of antidepressants used in cancer patients seem to be beneficial for the treatment of depression, anxiety, hot flashes and other symptoms such as sexual dysfunction, fatigue, nicotine dependence, vasomotor symptoms, executive functions, sleep problems, pruritus, as well as for hypochondriasis. "
02/01/2013 - "SSRIs are more effective against hypochondriasis and body dysmorphic disorder (BDD), and SNRIs appear to be more effective than other antidepressants when pain is the predominant symptom. "
08/03/2022 - "Factors found more among BD-2 > BD-1 cases included: [a] descriptors (more familial affective disorder, older at onset, diagnosis and first-treatment, more education, employment and higher socioeconomic status, more marriage and children, and less obesity); [b] morbidity (more general medical diagnoses, less drug abuse and smoking, more initial depression and less [hypo]mania or psychosis, longer episodes, higher intake depression and anxiety ratings, less mood-switching with antidepressants, less seasonal mood-change, greater %-time depressed and less [hypo]manic, fewer hospitalizations, more depression-predominant polarity, DMI > MDI course-pattern, and less violent suicidal behavior); [c] specific item-scores with initial HDRS21 (higher scores for depression, guilt, suicidality, insomnia, anxiety, agitation, gastrointestinal symptoms, hypochondriasis and weight-loss, with less psychomotor retardation, depersonalization, or paranoia); and [d] treatment (less use of lithium or antipsychotics, more antidepressant and benzodiazepine treatment). "

12/01/2008 - "More patients responded with improvement in hypochondriasis when given fluoxetine compared with placebo, starting at week 8 (50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs 33.3%, P = 0.05). "
12/01/2008 - "Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis."
01/01/2017 - "This study supports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis. "
12/01/2008 - "This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. "
12/01/2008 - "A double-masked, placebo-controlled study of fluoxetine for hypochondriasis."

05/01/2014 - "The follow-up was at most 6 years and was performed within the scope of a randomized controlled trial that investigated the efficacy of cognitive behavioral therapy, paroxetine, and placebo in hypochondriasis. "
01/01/2007 - "This study, to the authors' knowledge, is the first randomized controlled trial comparing the efficacy of cognitive behavior therapy (CBT), paroxetine, and a placebo (administered in a double blind fashion) in the treatment of hypochondriasis. "
07/01/2001 - "5. The results of this study suggest that patients with hypochondriasis may be responsive to paroxetine. "
07/01/2001 - "2. This open study evaluates the efficacy and tolerance of paroxetine in 11 patients with DSM-III-R hypochondriasis. "
07/01/2001 - "An open study of paroxetine in hypochondriasis."

07/01/2002 - "The results of this study suggest that nefazodone is a promising treatment for hypochondriasis. "
07/01/2002 - "Eleven patients with a primary diagnosis of DSM-IV hypochondriasis received an 8-week trial of nefazodone with a maximum dose of 600 mg/day and a mean dose of 432 mg. Clinician and self-ratings were completed at each of six visits. "
07/01/2002 - "The purpose of the present study was to evaluate the use of nefazodone in the treatment of hypochondriasis in an open-label trial. "
07/01/2002 - "An open-label clinical trial of nefazodone in hypochondriasis."

10/01/2017 - "DSM-5 IAD and SSD classifications reliably detect more cases of clinically significant health anxiety than DSM-IV Hypochondriasis. "
10/01/2017 - "Half the sample met criteria for DSM-IV Hypochondriasis; of those, 56% met criteria for SSD criteria, 36% for IAD, and 8% for comorbid IAD/SSD. "
10/01/2017 - "IAD and SSD were more reliable diagnoses than Hypochondriasis (kappa estimates: IAD: 0.80, SSD: 0.92, Hypochondriasis: 0.60). "
01/01/2016 - "The individuals originally diagnosed as DSM-IV hypochondriasis predominantly met criteria for SSD (74%) and rarely for IAD (26%). "
11/25/2019 - "It eliminated the diagnoses of somatisation disorder, undifferentiated somatoform disorder, hypochondriasis and pain disorder; most of the patients who previously received these diagnoses are now diagnosed in DSM-5 with SSD. "

10/01/1980 - "Hypnotic paradigm-substitution therapy in a case of hypochondriasis."
07/01/1948 - "Hypnotic neuroses; hypochondriasis and depression."
04/01/1982 - "Narcotic-sedative patients spent significantly more money on pain medication per month, reported significantly greater physical impairment, and had higher MMPI hypochondriasis and hysteria scores when compared to the other patients. "

01/01/2007 - "Compared to SSRI-treated patients, duloxetine-treated patients had a significantly greater (p < or = 0.05) reduction in the 17-item Hamilton Depression Rating Scale (HAMD17) total score and HAMD17 items of work and activities, psychomotor retardation, genital symptoms and hypochondriasis. "
06/30/2007 - "Successful treatment of refractory hypochondriasis with duloxetine."

12/01/1999 - "On the HAM-D, statistically significant improvement was noted on "depressed mood" (p <.0001), "feelings of guilt" (p <.01), "work and activities" (p <.001), "hypochondriasis" (p <.02), and "insomnia" (p <.01) at week 8. The mean dose of bupropion SR at endpoint was 222 mg/day, and the drug was relatively well tolerated. "

12/01/2001 - "After treatment, the average values of MMPI on falseness (F), hypochondriasis (HS), depression (D) and psychosthenia (Pt) in the treated group were all improved (P < 0.01 or P < 0.05); but in the control group, significant difference only showed in MMPI on HS (P < 0.05). "
07/01/1997 - "The results were analysed up to 6 months after treatment and showed the treated patients to be moderately but significantly improved with respect to physical illness and somatic preoccupation, hypochondriasis, and medication usage. "
10/01/2017 - "Seventy-five patients with a diagnosis of hypochondriasis who were previously treated with CT or ET were contacted 3 years after treatment. "
03/01/2016 - "Changes in negative implicit evaluations in patients of hypochondriasis after treatment with cognitive therapy or exposure therapy."
01/01/2011 - "Scores on the 3 measures of hypochondriasis were significantly decreased after treatment in the CBT compared with the control group. "

10/01/2014 - "Exposure-based cognitive-behavioural therapy (CBT) delivered via the internet has been shown to be effective for severe health anxiety (hypochondriasis) but has not been compared with an active, effective and credible psychological treatment, such as behavioural stress management (BSM). "
10/17/2007 - "Cognitive therapy, behavioural therapy, cognitive behavioural therapy and behavioural stress management are effective in reducing symptoms of hypochondriasis. "
01/01/2002 - "Cognitive behavioural therapy has been shown in controlled studies to be efficacious in the treatment of hypochondriasis. "
04/01/2000 - "The aim of the study was to evaluate the effectiveness of individual explanatory therapy in hypochondriasis. "
05/01/2019 - "Competence of therapists-in-training was assessed in a random sample of n = 30 videos on cognitive behavioural therapy including patients diagnosed with hypochondriasis. "

01/01/2017 - "Prior studies of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CBT). "
01/01/2000 - "To examine whether somatoform symptoms, specifically symptoms of conversion, somatization, and hypochondriasis, are associated with side-effect reporting and treatment nonadherence in depressed family medicine outpatients, and to measure whether symptoms improve with pharmacotherapy. "
01/01/1996 - "The pharmacotherapy of hypochondriasis."
12/01/1993 - "Hypochondriasis without concomitant depression is often considered to be unresponsive to pharmacotherapy. "
02/01/2011 - "Other disorders in the category include: somatization disorder, undifferentiated somatoform disorder, conversion disorder, hypochondriasis and body dysmorphic disorder Treatment is applied through a combination of pharmacotherapy and psychotherapy. "

05/01/2009 - "The present study aims to determine whether cognitive-behavioural minimal contact bibliotherapy is acceptable to participants suffering from DSM-IV-TR hypochondriasis, and whether this intervention is able to reduce hypochondriacal complaints, as well as comorbid depressive complaints and trait anxiety. "
05/01/2009 - "Cognitive-behavioural bibliotherapy for hypochondriasis: a pilot study."
10/01/1993 - "In this paper, behavioral intervention in an adult male with hypochondriasis is outlined The management involved progressive relaxation, behavioral counseling and bibliotherapy."

01/01/2023 - "The present study was conducted to identify the frequency and causes of self-medication and hypochondriasis among students. "
01/01/2023 - "There was a statistically significant association between hypochondriasis and self-medication (p = 0.002). "
01/01/2023 - "Hypochondriasis and self-medication among medical sciences students during the COVID-19 pandemic: A descriptive cross-sectional study in Northwestern Iran."